Morning Brief — Thursday, September 3, 2026

Market Overview

Futures are modestly higher pre-bell as Treasury yields ease off recent highs, giving growth stocks room to breathe after a punishing rate environment. The AI trade is firmly back in focus — Snowflake’s blowout quarter is the talk of the tape, dragging the broader software complex up with it, while NVIDIA rallies on a new Hugging Face partnership. Tech earnings quality has been strong this cycle, but bond bears are watching the 10-year closely as it hovers near 4.80%.

Claude’s Call

UP — The SNOW earnings beat is a genuine positive read-through for the entire data infrastructure/AI software complex, and easing yields provide a macro tailwind for duration-sensitive growth names. Expect the S&P 500 to push higher today, led by tech and software, with the rally broadening if the 10-year holds below 4.80%.

Top Movers

SNOW (+24.7%) — $381.37 → $450.02 (+18.0% upside) Thesis: This is as real as earnings catalysts get — AI-driven revenue acceleration that forced the Street to reprice the entire growth trajectory overnight. CEO Ramaswamy confirmed the company remains on track to break even next year, which answers the profitability skeptics. Technically, SNOW is at a 6-month high, hitting the top of its 20-day range — the move is real but the easy money was made in after-hours. The next logical target is the 1.272 Fibonacci extension at $450. Levels: Exit at $450.02 (fib ext 1.272). Support at $318.66 (fib 23.6%) — a long way down if this fades.

HCM (+14.62%) — $13.80 → $17.30 (+25.4% upside) Thesis: A $1.295 billion licensing deal with GSK for its KRAS-EGFR cancer therapy is a hard, bankable catalyst — $110 million upfront is real cash hitting the balance sheet. This is exactly the kind of validation that de-risks a small-cap oncology name, and Panmure/Cavendish reiterated buys, flagging a deep valuation disconnect. Technically, the stock is still 12% below the 6-month high of $15.74, and the 23.6% fib at $14.38 is the next hurdle — a clean break above that targets the 1.272 extension at $17.30. Levels: Exit at $17.30 (fib ext 1.272). Support at $13.54 (fib 38.2%) and the $11.61 SMA-50 below.

VRNS (+10.41%) — $46.76 → $55.81 (+19.3% upside) Thesis: Proofpoint (Thoma Bravo-backed) reportedly in acquisition talks — this is M&A premium, the strongest possible catalyst for a standalone cybersecurity name. Thoma Bravo knows the space cold, and Varonis’s data security platform is a natural bolt-on for Proofpoint’s email/collaboration security empire. Stock’s RSI is only 12.8 — deeply oversold on a longer-term basis, meaning the pre-deal price was already washed out. The stock is near the 6-month high of $48.19, and a confirmed deal would push toward the 1.272 extension at $55.81. Levels: Exit at $55.81 (fib ext 1.272). Support at $41.58 (fib 23.6%) and $43.54 SMA-50.

GTLB (+9.98%) — $49.59 → $58.85 (+18.7% upside) Thesis: GitLab beat on both revenue and earnings, hitting a 52-week high — this is a genuine earnings breakout, not sector sympathy. The DevSecOps platform is benefiting from AI-assisted coding tailwinds, and the beat validates that enterprise software spending is holding up better than feared. RSI at 33 means the stock was technically oversold heading into the print — the re-rating is justified and there’s room to run. The 1.272 fib extension at $58.85 is a reasonable near-term target. Levels: Exit at $58.85 (fib ext 1.272). Support at $43.10 (fib 23.6%) and $36.52 SMA-50.

CHTR (+8.74%) — $158.97 → $169.68 (+6.7% upside) Thesis: Charter is a deep-value recovery trade — the stock is down 82% over five years, RSI is at a jaw-dropping 7.45 (one of the most oversold readings I’ve seen), and analysts are calling it 50% undervalued. The CFO departure spooked the market yesterday, but the interim appointment of a long-tenured finance executive is not a crisis — it’s a management transition at a company already in turnaround mode. The bounce off multi-year lows is technically due. That said, the upside is limited near-term — the fib 61.8% resistance at $169.68 is only 6.7% away, and overhead supply from the 6-month decline is heavy. Levels: Exit at $169.68 (fib 61.8% from 6mo swing). Support at $142.54 (SMA-50) and $144.10 (20d low).

TARS (+11.76%) — $82.76 → $90.63 (+9.5% upside) Thesis: XDEMVY is a genuine commercial success story — 69% YoY growth to $173.9M in Q2, raised guidance, and now a pipeline expansion into retinal diseases via the Alkeus acquisition. The stock is at a 6-month high and technically extended, but the fundamental momentum is real. At 36x forward P/E vs. the peer median of ~16x, you’re paying for growth — but 69% revenue growth arguably justifies the premium on a PEG basis. Levels: Exit at $90.63 (fib ext 1.272). Support at $76.84 (fib 23.6%) and $65.34 SMA-50.

Headlines to Watch

“Snowflake Stock Jumps 23% After Earnings — Turning Into an AI Winner” — This is the most important read-through headline of the day: if SNOW can monetize AI at this scale, expect upgrades and multiple expansion across the cloud data platform space (DBTX, PLTR, MDB).
“VRNS Stock Jumps 10% As Thoma Bravo-Owned Proofpoint Weighs a Bid” — M&A in cybersecurity is heating up; watch names like SAIL, QLYS, and TENB for sympathy moves as acquirers scan the landscape.
“Broadcom Sitting at $370 as Wall Street Has Doubts About AI Business” — AVGO is the most-discussed name on WSB with 687 mentions, but the stock is 25% off its summer peak with long-dated options pricing in downside risk — earnings quality check needed before the December report.
“S&P 500 Got Cheaper While It Rallied — What Bond Bears Are Missing” — The market is trading at 19.6x forward earnings despite the 10-year at 4.80%; if yields stay sticky, this compression narrative breaks down fast and growth leads the reversal.
“HUTCHMED Shares Jump 17% on $1.3 Billion GSK Cancer Drug Deal” — Validates the licensing model for China-based oncology developers; read-through for other ex-China licensing plays like ZLAB and BeiGene.
“Charter Communications CFO Jessica Fischer Steps Down” — Leadership instability at a highly leveraged cable operator is a yellow flag; watch whether Howard’s interim role stabilizes or if a permanent search drags on through Q4.
“Affirm Rallies 6% on $104 Price Target From BofA as Yields Ease” — BNPL names are yield-sensitive; if the 10-year pulls back from 4.80%, AFRM, SEZL, and PYPL could extend the rally into week’s end.

Claude’s Top Picks

GTLB (+9.98% today, +19.04% week) — $49.59 → $58.85 (+18.7% upside) Valuation: No formal comp in the data, but as a DevSecOps SaaS name growing revenue at double-digit rates, a re-rating off a deeply oversold RSI of 33 is technically and fundamentally sound. Upside: Earnings beat drove a 52-week high breakout — institutions that were underweight now have to chase, and the AI coding tailwind is a multi-quarter story. Risk: If the broader software rally fades when yields tick back up, GTLB could give back half this move quickly — the stock tripled off the 6-month low and has no 200-day MA anchor.

HCM (+14.62% today, +11.74% week) — $13.80 → $17.30 (+25.4% upside) Valuation: Marked CHEAP vs. peers — valuation disconnect was explicitly flagged by both Panmure and Cavendish post-deal; the GSK $110M upfront alone begins to close that gap. Upside: The $1.295B total deal value dwarfs the current market cap — milestone payments and royalties provide a long runway of re-rating catalysts as the KRAS-EGFR therapy advances. Risk: The deal is contingent on clinical and regulatory milestones; any Phase III hiccup turns the $110M upfront into a ceiling rather than a floor.

VRNS (+10.41% today, +14.55% week) — $46.76 → $55.81 (+19.3% upside) Valuation: Technically expensive at 114x forward P/E vs. peer median of 39x, but M&A premium trumps valuation math — Thoma Bravo doesn’t buy cheap, they buy strategic. Upside: Acquisition talks mean any dip is a potential bid support level; Proofpoint needs VRNS’s data security capabilities to compete with Palo Alto and CrowdStrike’s expanding platforms. Risk: If talks break down (Proofpoint financing, regulatory scrutiny, or price disagreement), the stock gives back 15-20% to pre-rumor levels immediately — this is a binary trade.

TARS (+11.76% today, +15.83% week) — $82.76 → $90.63 (+9.5% upside) Valuation: Expensive at 36x forward P/E vs. 16x peer median, but 69% revenue growth on a PEG basis makes this more defensible than the raw multiple suggests — PEG of ~0.5 is genuinely cheap. Upside: XDEMVY is approaching blockbuster territory, the Alkeus acquisition adds a second pipeline asset in an area (Stargardt disease) with zero approved therapies, and guidance was raised. Risk: The stock is at a 6-month high with vol_vs_avg of just 0.04 — very thin volume on a big move is a yellow flag; conviction buyers aren’t necessarily showing up at the top.

CHTR (+8.74% today, +2.47% week) — $158.97 → $169.68 (+6.7% upside) Valuation: No forward comp provided, but the stock is down 82% over 5 years and analysts are calling it 50% undervalued — even applying a severe haircut to those targets, the stock screens cheap on EV/EBITDA for a mature cable operator. Upside: RSI of 7.45 is statistical rubber-band territory — mean-reversion alone argues for a 10-15% bounce, and the Liberty Broadband merger integration provides a medium-term re-rating catalyst. Risk: The CFO departure is genuinely unsettling for a heavily leveraged balance sheet — debt markets will want to see a permanent, credible CFO before re-rating the equity; the 6-month downtrend is brutal and overhead resistance is everywhere.

Avoid

SNOW — Already up 24.7% on the day and sitting at the 6-month high with no 200-day MA; the fundamental story is now well-understood and priced in at 130x forward P/E (vs. 16x peer median). Chasing a +25% gap-up in a pre-profit software name with RSI already reversing up from 29 is a momentum trap — wait for the $318 fib 23.6% pullback to build a position with real risk/reward.

FTH (+13.36%) — Volume ratio of just 0.02 on a 13% move at the 6-month high is a massive red flag — this has all the hallmarks of a low-float squeeze with zero institutional conviction. The 72% analyst upside target sounds great until you notice the stock has effectively no news catalyst in the data other than a momentum article and a dividend notice from a different company entirely (Frontier Transport Holdings, JSE-listed). Hard pass.

GENVR (+9.67%, +42.57% week) — Up 42% in a week on a $5 stock with volume ratio of 0.15 and no company-specific news I can identify in the data — the news in the feed is about Gen Digital (GEN), a completely different company. This looks like a ticker confusion or low-float manipulation play. Approaching the 6-month high at $5.20 with fib extensions far overhead; the exit is never as easy as the entry on names like this.

WSB Sentiment Check

AVGO — WSB says: BULLISH (80% bullish) Claude says: PARTIALLY AGREE — The AI revenue story is genuine (nearly doubled in a quarter), but at $346 with the stock 25% off its summer high and long-dated options pricing in downside before December earnings, 80% bullish sentiment feels complacent. The technicals show price below the SMA-50 ($383) and below the fib 61.8% at $364 — this is not a clean chart. Sentiment is ahead of the setup.

NVDA — WSB says: BULLISH (80% bullish) Claude says: AGREE — The Hugging Face partnership is incremental but directionally right, and NVDA is consolidating just below the 6-month high of $235 with the SMA-50 at $209 as a solid floor. The chart is constructive — higher lows, trend intact, and the AI capex cycle shows no signs of rolling over. WSB has it right here; this is the most defensible large-cap AI long.

SNOW — WSB says: BULLISH (80% bullish) Claude says: DISAGREE for new entries — The quarter was fantastic, the AI narrative is real, and the stock deserves to be higher — but 80% bullish after a 25% gap means the easy money is gone. At $381, the stock is at the 6-month high, 130x forward P/E, and RSI of 29 was actually the buy signal before earnings. Chasing here with no 200-day MA and negative EV/EBITDA is a recipe for holding a bag when the next rate scare hits. Wait for the pullback.

HPE — WSB says: BULLISH (80% bullish) Claude says: DISAGREE — HPE is moving in sympathy with the AI server/data center narrative, but the stock is below its SMA-50 ($49.75) and just broke below the fib 38.2% support at $44.95 — technically this is a downtrend, not a breakout. The vol ratio of 0.28 is moderate, not conviction. If SNOW’s blowout gets you excited about HPE servers, that’s two degrees of separation from a real catalyst.

MU — WSB says: MIXED (55% bullish) Claude says: PARTIALLY AGREE — The mixed sentiment is actually the most intellectually honest read in the WSB feed today. MU is a memory cyclical trading at $930 — well below the 6-month high of $1,213 — and the 38.2% fib at $872 is nearby support. The AI-driven HBM demand is real, but DRAM/NAND cycles are notoriously hard to time. The setup is choppy: support is close but so is a breakdown. Wait for a clean hold of $930 before adding.

Earnings Scorecard

SNOW — BEAT (AI-driven revenue acceleration) | Stock: +24.7% | Reported: Wednesday After Close The reaction is mostly justified — a genuine top-line beat driven by AI workload adoption is exactly what the market needed to see after a long period of underwhelming cloud spending growth. However, EPS of -$3.18 means this is still a loss-making business trading at 130x forward earnings. The +24.7% gap is pricing in a lot of future execution. Buy-the-dip on a pullback to $318-$320 (fib 23.6%), not at current levels.

CIEN — BEAT (raised fiscal 2026 revenue outlook) | Stock: -7.64% | Reported: Wednesday The sell-the-news reaction is overdone in my view — Ciena beat estimates AND raised guidance on AI-driven optical networking demand, yet fell 7.6%. This smells like profit-taking after a strong run, not a fundamental deterioration. With an analyst target of $551 vs. the current ~$490 implied by the reaction, this is a buy-the-dip — CIEN is the picks-and-shovels play for AI datacenter buildout and the market just handed you a discount.

ADYEY — BEAT (raised growth guidance, acquisitions lifting revenue target) | Stock: +3.97% | Reported: Recent A 4% gain on a raised revenue target and strong H1 is actually an underwhelming reaction — the stock likely has more room. The muted move suggests the market is still skeptical about acquisition integration. Watch for follow-through if the broader fintech complex (PYPL, AFRM) continues to rally on yield relief. Hold for now — the story is intact but the reaction size signals no urgency.

PATH — BEAT (Q2 revenue and earnings beat) | Stock: +3.83% | Reported: Recent A 4% move on a beat is underwhelming for an enterprise AI automation name. The modest reaction either reflects that expectations were already elevated heading in, or that the market isn’t fully buying the AI agent monetization narrative yet. Analyst target is only $13.87 vs. the implied current price — this doesn’t scream upside. Hold — not a compelling swing trade at current levels.

This brief is for informational purposes only and does not constitute financial advice. Past technical setups do not guarantee future performance. All positions carry risk of loss.